Medicare Part D Gross Spending on GLP-1s Increased Five-Fold Between 2019 and 2024, But Estimated Rebates of Around 50% Mean That Net Spending is Much Lower Gross Medicare Part D spending on GLP-1s in 2024 (not accounting for rebates) totaled $27.5 billion, a five-fold increase from 2019, reflecting an expansion in use of GLP-1s with more recent FDA approvals for type 2 diabetes
There is a follow-up period involved with this study of up to 14 months which is still occurring
A natural path to growth hormone optimization Still unsure whether HGH peptides or synthetic HGH is the better choice
By increasing GH levels, Sermorelin/Ipamorelin can also help improve energy levels and reduce fatigue
Lhteenvuo M, Tiihonen J, Solismaa A, et al
A common and dangerous mistake is continuing to draw the same number of units from a new concentration vial